Open Nav

OncoSenX, Inc

  • Matthew Scholz, OncoSenX

Meet potential Series A investors and Pharma collaborators

  • Date:Wednesday, October 17
  • Time:9:15 AM - 9:30 AM
  • Room:Elizabethan A
  • Location:2nd Floor
  • Session Type:Company Presentation
  • Presentation Type:Privately Funded Company
  • Company Description/Mission Statement:OncoSenX targets solid tumors based on transcriptional activity using a unique lipid nanoparticle and plasmid DNA. Our treatment delivers a simple genetic program that induces apoptosis in cancerous cells. Our approach is a less invasive, more precise intervention for this complex and devastating disease.
  • Company
  • Company HQ City:Seattle, WA
  • Company HQ Country:United States
  • Company HQ State:Washington‚ State 
  • CEO/Top Company Official:Matthew Scholz
  • Year Founded:2018
  • Main Therapeutic Focus:Oncology
  • Lead Product in Development :LNP-delivered DNA targeting solid tumors with elevated levels of p53 transcription factors
  • Development Phase of Primary Product:Pre-Clinical
  • Size of Last Investment Round:$2M
  • Total Amount Raised to Date, In All Rounds:$2M
Matthew Scholz